Sifting through countless of stocks in the Health Care Providers & Services industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Guardant Health, Inc., Maravai LifeSciences Holdings or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Guardant Health, Inc., Maravai LifeSciences Holdings and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Guardant Health, Inc., Maravai LifeSciences Holdings and Inc.

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The CYGNUS segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and emerging biopharmaceutical and life sciences research companies; and academic research institutions and diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.

Latest Health Care Providers & Services and Guardant Health, Inc., Maravai LifeSciences Holdings, Inc. Stock News

As of September 1, 2026, Guardant Health, Inc. had a $22.1 billion market capitalization, compared to the Health Care Providers & Services median of $1.8 million. Guardant Health, Inc.’s stock is up 55.8% in 2026, down 6.9% in the previous five trading days and up 143.86% in the past year.

Currently, Guardant Health, Inc. does not have a price-earnings ratio. Guardant Health, Inc.’s trailing 12-month revenue is $1.2 billion with a -38.3% net profit margin. Year-over-year quarterly sales growth most recently was 44.3%. Analysts expect adjusted earnings to reach $-1.455 per share for the current fiscal year. Guardant Health, Inc. does not currently pay a dividend.

As of September 1, 2026, Maravai LifeSciences Holdings, Inc. had a $1.1 billion market cap, putting it in the 46th percentile of all stocks. Maravai LifeSciences Holdings, Inc.’s stock is up 127.5% in 2026, down 16.9% in the previous five trading days and up 201.65% in the past year.

Currently, Maravai LifeSciences Holdings, Inc. does not have a price-earnings ratio. Maravai LifeSciences Holdings, Inc.’s trailing 12-month revenue is $208.8 million with a -37.1% net profit margin. Year-over-year quarterly sales growth most recently was 8.4%. Analysts expect adjusted earnings to reach $-0.181 per share for the current fiscal year. Maravai LifeSciences Holdings, Inc. does not currently pay a dividend.

How We Compare Guardant Health, Inc., Maravai LifeSciences Holdings and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Guardant Health, Inc., Maravai LifeSciences Holdings and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Guardant Health, Inc., Maravai LifeSciences Holdings and Inc. Stock Value Grades

Company	Ticker	Value
Guardant Health, Inc.	GH	na
Maravai LifeSciences Holdings, Inc.	MRVI	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Guardant Health, Inc. does not have a meaningful Value Score. Maravai LifeSciences Holdings, Inc. has a Value Score of 13, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither Guardant Health, Inc., Maravai LifeSciences Holdings or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Guardant Health, Inc., Maravai LifeSciences Holdings or Inc. is the better investment when it comes to value.

Guardant Health, Inc., Maravai LifeSciences Holdings and Inc. Growth Grades

Company	Ticker	Growth
Guardant Health, Inc.	GH	D
Maravai LifeSciences Holdings, Inc.	MRVI	F

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Guardant Health, Inc. has a Growth Score of 29, which is Weak. Maravai LifeSciences Holdings, Inc. has a Growth Score of 8, which is Very Weak.

The Growth Stock Winner: No Clear Winner

Neither Guardant Health, Inc., Maravai LifeSciences Holdings or Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Guardant Health, Inc., Maravai LifeSciences Holdings or Inc. is the better investment when it comes to sustainable growth.

Guardant Health, Inc., Maravai LifeSciences Holdings and Inc.’s Quality Grades

Company	Ticker	Quality
Guardant Health, Inc.	GH	D
Maravai LifeSciences Holdings, Inc.	MRVI	C

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Guardant Health, Inc. has a Quality Score of 37, which is Weak. Maravai LifeSciences Holdings, Inc. has a Quality Score of 57, which is Average.

The Quality Stock Winner: No Clear Winner

Neither Guardant Health, Inc., Maravai LifeSciences Holdings or Inc. has a high enough Quality Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Guardant Health, Inc., Maravai LifeSciences Holdings or Inc. is the better investment when it comes to quality.

Other Guardant Health, Inc., Maravai LifeSciences Holdings and Inc. Grades

In addition to Value, Growth and Quality, A+ Investor also provides grades for Momentum and Estimate Revisions.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Guardant Health, Inc., Maravai LifeSciences Holdings and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Guardant Health, Inc., Maravai LifeSciences Holdings or Inc. Stock?

Overall, Guardant Health, Inc. stock has a Value Score of , Growth Score of 29 and Quality Score of 37.

Maravai LifeSciences Holdings, Inc. stock has a Value Score of 13, Growth Score of 8 and Quality Score of 57.

Comparing Guardant Health, Inc., Maravai LifeSciences Holdings and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.